Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

Blood

Volumn 102, Issue 7, 2003, Pages 2379-2386

  Kantarjian, Hagop ^a   Gandhi, Varsha ^b   Cortes, Jorge ^b   Verstovsek, Srdan ^b   Du, Min ^b   Garcia Manero, Guillermo ^b   Giles, Francis ^b   Faderl, Stefan ^b   O'Brien, Susan ^b   Jeha, Sima ^b   Davis, Jan ^b   Shaked, Zeev ^b   Craig, Adam ^b   Keating, Michael ^b   Plunkett, William ^b   Freireich, Emil J ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; MITOXANTRONE; NUCLEOSIDE DERIVATIVE; PREDNISONE; THALIDOMIDE; TOPOTECAN; TROXACITABINE; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLAST CELL; BLOOD TOXICITY; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG HALF LIFE; DRUG INFUSION; DRUG MECHANISM; DRUG RESPONSE; FEMALE; HAND FOOT SYNDROME; HIGH RISK POPULATION; HUMAN; INFECTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RASH; SALVAGE THERAPY; SEPSIS; THROMBOCYTE COUNT; TREATMENT OUTCOME; VOMITING;

EID: 0141482004     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-03-0925     Document Type: Article

References (40)

1. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive post remission chemotherapy in adults with acute myelold leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994;331:896-903.
2. Fosså A, Santoro A, Hiddemann W, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3786-3792.
3. Silverman LR, Demakos EP, Bercedis L, et al. A randomized controlled trial of azacitidine in patients with myelodysplastic syndrome; a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429-2440.
4. Wijermans P, Lübbert M, Verhoef G, et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000;18:956-962.
5. Goodman GR, Burian C, Koziol JA, Saven, A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol. 2003;21:891-896.
6. Gandhi V, Plunkett W, Weller S, et al. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics and pharmacodynamics in leukemia cells. J Clin Oncol. 2001;19:2142-2132.
7. Keating MJ, O'Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998;92:1165-1171.
8. Estey E, Thall P, Andreeff M, et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol. 1994;12:671-678.
9. Warrell R, Berman E. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol. 1986;4:74-79.
10. Spriggs DR, Stopa E, Mayer RJ, Schoene W, Kufe DW. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathoiogical study. Cancer Res. 1986;46:5953-5958.
11. Vahdat L, Wong ET, Wile MJ, Rosenblum M, Foley KM, Warrell RP Jr. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood. 1994;84:3429-3434.
12. Montgomery JA, Shortnacy-Fowler AT, Clayton SD, Riordan JM, Secrist JA III. Synthesis and biologic activity of 2′-fluoro-2-halo derivatives of 9-b-D-arabinofuranosyladenine. J Med Chem. 1992;35:397-401.
13. Avramis VI, Plunkett W. 2-Fluoro-ATP: a toxic metabolite of 9-b-D-arabinofuranosyl-2-fluoroadenine. Biochem Biophys Res Comm. 1983;113:35-43.
14. Avramis VI, Plunkett W. Metabolism of 9-b-D-arabinofuranosyl-2-fluoroadenine 5′-phosphate by mice beadng P388 leukemia. Cancer Drug Delivery. 1983;1:1-10.
15. Huang P, Plunkett W. Phosphorolytic cleavage of 2-fluoroadenine from 9-b-D-arabinofuranosyl-2-fluoroadenine by Escherichia coli: a pathway for 2-fluoro-ATP production. Biochem Pharm. 1987;36:2945-2952.
16. Parker WB, Allan PW, Hassan AE, Secrist JA III, Sorscher EJ, Waud WR. Antitumor activity of 2-fluoro-2′-deoxyadenosine against tumors that express Eschedchia coli purine nucleoside phosphorylase. Cancer Gene Ther. 2003;10:23-29.
17. Carson DA, Wasson DB, Esparza LM, Carrera CJ, Kipps TJ, Cottam HB. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2′ -arabino-fluoro-2′deoxyadenosine. Proc Natl Acad Sci U S A. 1992;89:2970-2974.
18. Parker WB, Shaddix SC, Chang CH, et al. Effects of 2-chloro-9-(2-deoxy-2-fluoro-b-D-arabino-furanosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-trisphosphate. Cancer Res. 1991;51:2386-2394.
19. Parker WB, Shaddix SC, Rose LM., et al. Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro-b-D-ribofuranosyl)adenine, 2-chloro-9-(2-deoxy-2,2-difluoro-b-D-ribofuranosyl)adenine in CEM cells. Mol Pharmacol. 1999;55:515-520.
20. Plunkett W, Gandhi V. Purine and pyrimidine nucleoside analogs: cancer chemotherapy and biological response modifiers. In: Giaocone G, Schilsky R, Sondel P, eds. Annual 19. Amsterdam, The Netherlands: Elsevier Science BV; 2001:21-45.
21. Parker WB, Bapat AR, Shen JX, Townsend AJ, Cheng YC. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol Pharmacol. 1988;34:485-491.
22. Xie C, Plunkett W. Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)adenine in human lymphoblastoid cells. Cancer Res. 1995;55:2847-2852.
23. Xie KC, Plunkett W. Deoxynucleotide pool deletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-(2-deoxy-fluoro-b-D-arabinofuranosyl)adenine. Cancer Res. 1996;56:3030-3037.
24. Kantarjian H, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine (Cl-F-ara-A; 2 chloro-2′ -fluoro-deoxy-9-beta-D-arabinofuranosyladenine) in patients with solid and hematologic cancers. J Clin Oncol. 2003;21:1167-1173.
25. Plunkett W, Hug V, Keating M, et al: Quantitation of 1-β -D-arabinofuranosylcytosine 5κ-triphosphate in the leukemic cells from bone marrow and pedpheral blood of patients receiving 1-β -D-arabinofuranosylcytosine therapy Cancer Res. 1980;40:588-591.
26. Gandhi V, Chen W, Ayres M, et al. Plasma and cellular pharmacology of 8-chloro-adenosine in mice and rats. Cancer Chemother Pharmacol. 2002;50:85-94.
27. Rodriguez CO Jr, Plunkett W, Paff MT, et al. A high-pressure liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells. J Chromatography B. 2002;745:421-430.
28. Krance RA, Hurwitz CA, Head DR, et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J Clin Oncol. 2001;9:2804-2811.
29. Gandhi V, Kemena A, Keating MJ, Plunkett W. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leukemia Lymphoma. 1993;10:49-56.
30. Albertioni F, Lindemalm S, Reichelova V, et al. Pharmacokinetics of cladribine in plasma and its 5′-monophosphate and 5′-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. Clin Cancer Res. 1998;4:653-658.
31. Kemena A, Gandhi V, Shewach D, Keating MJ, Plunkett W. Inhibition of fludarabine metabolism by arabinosylcytosine during therapy. Cancer Chemother Pharmacol. 1992;31:193-199.
32. Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of arabinosylcytosine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993;11:116-124.
33. Crews KR, Gandhi V, Srivastava DK, et al. An interim analysis of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol. 2002;20:4217-4224.
34. Gandhi V, Estey E, Keating MJ, Chucrallah A, Plunkett W. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood. 1996;87:156-164.
35. Jeha S, Gandhi V, Chan KW, et al. Phase I study of clofarabine (Clofarex®) in pediatric leukemia [abstract]. Blood. 2002;199:86a.
36. Foran J, Wetzler M, Kantarjian H, et al. A phase II, open-label study of Clofarex® in adult patients with refractory or relapsed acute myelogenous leukemia [abstract]. Blood. 2002;100:271b.
37. Jeha S, Steinherz P, Altman A, et al, A phase II, open-label study of Clofarex® in pediatric patients with refractory or relapsed acute-myelogenous or lymphoblastic leukemia [abstract]. Blood, 2002;100:271b.
38. Gandhi V, Huang P, Chapman AJ, et al. Incorporation of fludarabine- and arabinosylcytosine-5′-triphosphates by DNA polymerase a: affinity, interaction, and consequences. Clin Cancer Res. 1997;3:1347-1355.
39. Cooper T, Nowak B, Gandhi V. Biochemical modulation of cytarabine triphosphate by clofarabine [abstract]. Proc AACR. 2003;44:142.
40. Yamauchi T, Nowak B, Keating MJ, Plunkett W, DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res. 2001;7:3580-3589.